Immunodominance in mouse and human CD4+ T-cell responses specific for the bordetella pertussis virulence factor P.69 pertactin

Infection and Immunity

Volumn 77, Issue 2, 2009, Pages 896-903

  Stenger, Rachel M ^a   Poelen, Martien C M ^a   Moret, Ed E ^b   Kuipers, Betsy ^a   Bruijns, Sven C M ^a   Hoogerhout, Peter ^a   Hijnen, Marcel ^c,d   King, Audrey J ^c   Mooi, Frits R ^c   Boog, Claire J P ^a   Van Els, Cécile A C M ^a  

^a NETHERLANDS VACCINE INSTITUTE   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

^d MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CELL ADHESION MOLECULE; CYTOKINE; EPITOPE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA DQ ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; P.69 PERTACTIN; PERTACTIN; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRULENCE FACTOR; BORDETELLA VIRULENCE FACTOR; OUTER MEMBRANE PROTEIN;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN RECOGNITION; ARTICLE; BORDETELLA BRONCHISEPTICA; BORDETELLA PERTUSSIS; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; MOUSE; NONHUMAN; PERTUSSIS; PRIORITY JOURNAL; SPLEEN CELL; TH1 CELL; TH17 CELL; AMINO ACID SEQUENCE; ANIMAL; BAGG ALBINO MOUSE; CELL LINE; CELL PROLIFERATION; CHEMISTRY; GERMFREE ANIMAL; IMMUNOLOGY; METABOLISM; MOLECULAR GENETICS;

AMINO ACID SEQUENCE; ANIMALS; BACTERIAL OUTER MEMBRANE PROTEINS; BORDETELLA PERTUSSIS; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; CELL PROLIFERATION; CYTOKINES; FEMALE; HLA-DQ ANTIGENS; HUMANS; IMMUNODOMINANT EPITOPES; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; SPECIFIC PATHOGEN-FREE ORGANISMS; VIRULENCE FACTORS, BORDETELLA; WHOOPING COUGH;

EID: 60549116672     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00769-08     Document Type: Article

References (51)

1. Ad Hoc Group for the Study of Pertussis Vaccines. 1988. Placebo-controlled trial of two acellular pertussis vaccines in Sweden-protective efficacy and adverse events. Lancet i:955-960.
2. Andrews, R., A. Herceg, and C, Roberts, 1997. Pertussis notifications in Australia, 1991 to 1997. Commun. Dis. lntell. 21:145-148.
3. Ausiello, C. M., F. Urbani, A. la Sala, R. Lande, and A. Cassone. 1997. Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines. Infect, Immun. 65:2168-2174.
4. Bach, J, F. 2002. The effect of infections on susceptibility to autoimmune and allergic diseases. N. Engl. J. Med. 347:911-920.
5. Bass, J. W., and R. R. Wittier. 1994. Return of epidemic pertussis in the United States. Pediatr. Infect. Dis. J. 13:343-345.
6. Canaday, D. H., A. Gehring, E. G. Leonard, B. Eilertson, J. R. Schreiber, C. V. Harding, and W. H. Boom. 2003. T-cell hybridornas from HLA-transgenic mice as tools for analysis of human antigen processing. J. Immunol. Methods 281:129-142.
7. Cherry, J. D., J. Gornbein, U. Heininger, and K. Stehr. 1998. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 16:1901-1906.
8. Crowcroft, N. S., and R. G. Pebody. 2006. Recent developments in pertussis. Lancet 367:1926-1936.
9. de Melker, H. E., M. A. Conyn-van Spaendonck, H. C. Rumke, J. K. van Wijngaarden, F. R. Mooi, and J. F. Schellekens. 1997. Pertussis in The Netherlands: an outbreak despite high levels of immunization with whole-cell vaccine. Emerg. Infect. Dis. 3:175-178.
10. Denoel, P., F. Godfroid, N. Guiso, H. Hallander, and J. Poolman. 2005. Comparison of acellular pertussis vaccines-induced immunity against infection due to Bordetella pertussis variant isolates in a mouse model. Vaccine 23:5333-5341.
11. De Serres, G-, N. Boulianne, F. M. Douville, and B. Duval. 1995. Pertussis in Quebec: ongoing epidemic since the late 1980s. Can. Commun. Dis. Rep. 21: 45-48.
12. Emsley, P., I. G. Charles, N. F. Fairweather, and N. W. Isaacs. 1996. Structure of Bordetella pertussis virulence factor P.69 pertactin. Nature 381:90-92.
13. Giuliano, M., P. Mastrantonio, A. Giammanco, A. Piscitelli, S. Salmaso, and S. G. Wassilak. 1998. Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis. J. Pediatr. 132:983-988.
14. Godfroid, F., P. Denoel, and J. Poolman. 2005. Are vaccination programs and isolate polymorphism linked to pertussis re-emergence? Expert Rev. Vaccines 4:757-778.
15. Guris, D., P. M. Strebel, B. Bardenheier, M. Brennan, R. Tachdjian, E. Finch, M. Wharton, and J. R. Livengood. 1999. Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults. 1990-1996. Clin. Infect. Dis. 28:1230-1237.
16. Gustafsson, L., H. O. Hallander, P. Olin, E. Reizenstein, and J. Storsaeter. 1996. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N. Engl. J. Med. 334:349-355.
17. Gzyl, A., E. Augustynowicz, D. Rabczenko, G. Gniadek, and J. Slusarczyk. 2004. Pertussis in Poland. Int. J. Epidemiol. 33:358-365.
18. Gzyl, A., E. Augustynowicz, I. van Loo, and J. Slusarczyk. 2001. Temporal nucleotide changes in pertactin and pertussis toxin genes in Bordetella pertussis strains isolated from clinical cases in Poland. Vaccine 20:299-303.
19. He, Q., and J. Mertsola. 2008. Factors contributing to pertussis resurgence. Future Microbiol. 3:329-339.
20. Higgins, S. C, A. G. Jarnicki, E. C. Lavelle, and K. H. Mills. 2006. TLR4 mediates vaccine-induced protective cellular immunity to Bordetella pertussis: role of lL-17-producing T cells. J. Immunol. 177:7980-7989.
21. Hijnen, M., Q. He, R. Schepp, P. Van Gageldonk, J. Mertsola, F. R. Mooi, and G. A. Berbers. 2008. Antibody responses to defined regions of the Bordetella pertussis virulence factor pertactin. Scand. J. Infect. Dis. 40:94-104.
22. Hijnen, M., P. G. van Gageldonk, G. A. Berbers, T. van Woerkom, and F. R. Mooi. 2005. The Bordetella pertussis virulence factor P.69 pertactin retains its immunological properties after overproduction in Escherichia coli. Protein Expr. Purif. 41:106-112.
23. Kasuga, T., Y. Nakase, K. Ukishima, and K. Takatsu. 1954. Studies on Haemophilus pertussis. IV. Preventive potency of each phase organisms of H. pertussis in mice. Kitasato Arch. Exp. Med. 27:49-55.
24. Khelef, N., B. Danve, M. J. Quentin-Millet, and N. Guiso. 1993. Bordetella pertussis and Bordetella parapertussis: two immunologically distinct species. Infect. Immun. 61:486-490.
25. King, A. J., G. Berbers, H. F. van Oirschot, P. Hoogerhout, K. Knipping, and F. R. Mooi. 2001. Role of the polymorphic region 1 of the Bordetella pertussis protein pertactin in immunity. Microbiology 147:2885-2895.
26. + T cells for key functions other than specific antibody production. J. Exp. Med. 191:1841-1852.
27. Mahon, B. P., M. T. Brady, and K. H. Mills. 2000. Protection against Bordetella pertussis in mice in the absence of detectable circulating antibody: implications for longterm immunity in children. J. Infect. Dis. 181:2087- 2091.
28. Mascart, F., M, Hainaut, A. Peltier, V, Verscheure, J. Levy, and C. Locht. 2007. Modulation of the infant immune responses by the first pertussis vaccine administrations. Vaccine 25:391-398.
29. Miller, E. 1999. Overview of recent clinical trials of acellular pertussis vaccines. Biologicals 27:79-86.
30. Mills, K. H. 2001. Immunity to Bordetella pertussis. Microbes Infect. 3:655-677.
31. Mills, K. H., A. Barnard, J. Watkins, and K. Redhead. 1993. Cell-mediated immunity to Bordetella pertussis: role of Thl cells in bacterial clearance in a murine respiratory infection model. Infect. Immun. 61:399-410.
32. Mills, K. H., M. Ryan, E. Ryan, and B. P. Mahon. 1998. A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis. Infect. Immun. 66:594-602.
33. Mobberley-Schuman, P. S., and A. A. Weiss. 2005. Influence of CR3 (CDllb/CD18) expression on phagocytosis of Bordetella pertussis by human neutrophils. Infect. Immun. 73:7317-7323.
34. Mooi, F. R., H. Hallander, C. H. Wirsing von Konig, B. Hoet, and N. Guiso. 2000. Epidemiological typing of Bordetella pertussis isolates: recommendations for a standard methodology. Eur. J. Clin. Microbiol. Infect. Dis. 19: 174-181.
35. Mooi, F. R., I. H. van Loo, and A. J. King. 2001. Adaptation of Bordetella pertussis to vaccination: a cause for its reemergence? Emerg. Infect. Dis. 7:526-528.
36. Mooi, F. R., H. van Oirschot, K. Heuvelman, H, G. van der Heide, W. Gaastra, and R. J. Willems. 1998. Polymorphism in the Bordetella pertussis virulence factors P.69/pertactin and pertussis toxin in The Netherlands: temporal trends and evidence for vaccine-driven evolution. Infect. Immun. 66: 670-675.
37. Plotkin, S. A., and M. Cadoz. 1997. The acellular pertussis vaccine trials: an interpretation. Pediatr. Infect. Dis. J. 16:508-517.
38. Redhead, K., J. Watkins, A. Barnard, and K. H. Mills. 1993. Effective immunization against Bordetella pertussis respiratoiy infection in mice is dependent on induction of cell-mediated immunity. Infect. Immun. 61:3190-3198.
39. Ryan, M., G. Murphy, L. Gothefors, L. Nilsson, J. Storsaeter, and K. H. Mills. 1997. Bordetella pertussis respiratoiy infection in children is associated with preferential activation of type 1 T helper cells. J. Infect. Dis. 175:1246-1250.
40. Ryan, M., G. Murphy, E. Ryan, L. Nilsson, F. Shackley, L. Gothefors, K. Oymar, E. Miller, J. Storsaeter, and K. H. Mills. 1998. Distinct T-cell subtypes induced with whole cell and acellular pertussis vaccines in children. Immunology 93:1-10.
41. + T cell help for antibody responses to a large viral pathogen: deterministic linkage of specificities. Immunity 28:847-858.
42. Simitsek, P. D., D. G. Campbell, A. Lanzavecchia, N. Fairweather, and C. Watts. 1995. Modulation of antigen processing by bound antibodies can boost or suppress class II major histocompatibility complex presentation of different T cell determinants. J. Exp. Med. 181:1957-1963.
43. Skorupski, K., and R. K. Taylor. 1996. Positive selection vectors for allelic exchange. Gene 169:47-52.
44. Stibitz, S., W. Black, and S. Falkow. 1986. The construction of a cloning vector designed for gene replacement in Bordetella pertussis. Gene 50:133- 140.
45. Storsaeter, J., H. O. Hallander, L. Gustafsson, and P. Olin. 1998. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 16:1907-1916.
46. g7 molecules show common sequence specificity. J. Clin, lnvestig. 115:2268-2276.
47. Thalen, M., J. van den Ijssel, Wr. Jiskoot, B. Zomer, P. Roholl, C. de Gooijer, C. Beuvery, and J. Tramper. 1999. Rational medium design for Bordetella pertussis: basic metabolism. J. Biotechnol. 75:147-159.
48. Tsang, R, S., A, K. I an. M, L. Sill, S, A. Halperin, P. Van Caeseele, F. Jamieson, and I. E. Martin. 2004. Polymorphisms of the fimbria fim3 gene of Bordetella pertussis strains isolated in Canada. J. Clin. Microbiol. 42:5364- 5367.
49. Watts, C, and A. Lanzavecchia. 1993. Suppressive effect of antibody on processing of T cell epitopes. J. Exp. Med. 178:1459-1463.
50. Wendelboe, A. M., A. Van Rie, S. Salmaso, and J. A. Englund. 2005. Duration of immunity against pertussis after natural infection or vaccination. Pediatr. Infect. Dis. J. 24:S58-S61.
51. White, J., M. Blackman, J. Bill, J, Kappler, P. Marrack, D. P. Gold, and W. Born. 1989. Two better cell lines for making hybridomas expressing specific T cell receptors. J. Immunol. 143:1822-1825.